{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:11:02Z","timestamp":1790079062504,"version":"4.0.1"},"reference-count":95,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiac amyloidosis (CA) is an under-recognized cause of heart failure. Its prevalence in screening studies, and the extent to which selective confirmatory testing affects prevalence estimates, remain uncertain across clinical settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed\/MEDLINE and EMBASE up to 10 August 2025. Two reviewers independently screened studies and extracted data. We grouped studies by clinical setting and combined prevalence estimates using random-effects meta-analysis. For each study, we calculated CA prevalence in (1) the whole enrolled cohort and (2) the subgroup who underwent confirmatory testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty-three studies were included. Pooled CA prevalence (whole cohort; tested subgroup) was highest in left ventricular hypertrophy\/hypertrophic cardiomyopathy [LVH\/HCM] (15.1%; 35.4%), followed by heart failure (HF)\u2014mainly HF with preserved or mildly reduced ejection fraction (HFpEF\/HFmrEF)\u2014(12.6%; 13.6%) and aortic stenosis (AS) (9.6%; 11.6%). Orthopaedic cohorts were lower overall (4.1%) but higher in tested subgroups (12.4%); \u2018no specific red flags\u2019 showed 1.8% vs. 7.8%; non-cardiac bone scintigraphy was 0.49% in both denominators. Across settings, transthyretin CA predominated over light-chain CA. Several studies approached systematic screening in the general elderly; however, they were few and still applied referral criteria to second-level examinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This meta-analysis shows that CA is relatively frequent in HFpEF\/HFmrEF, severe AS, and LVH\/HCM. To obtain reliable population estimates, future studies should test either all eligible participants or a predefined random sample, rather than only those with suspected disease. In clinical practice, screening strategies should clearly define which higher-risk individuals are referred for second-level tests, balancing diagnostic yield with feasibility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag172","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:40:36Z","timestamp":1781955636000},"source":"Crossref","is-referenced-by-count":2,"title":["Prevalence of cardiac amyloidosis in screening studies: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-9519","authenticated-orcid":false,"given":"Alberto","family":"Aimo","sequence":"first","affiliation":[{"name":"Health Sciences Interdisciplinary Center, Scuola Superiore Sant\u2019Anna , piazza Martiri della Libert\u00e0 33, 56127 Pisa ,","place":["Italy"]},{"name":"Cardiology Division, Fondazione Toscana Gabriele Monasterio , via Moruzzi 1, 56124 Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Castiglione","sequence":"additional","affiliation":[{"name":"Health Sciences Interdisciplinary Center, Scuola Superiore Sant\u2019Anna , piazza Martiri della Libert\u00e0 33, 56127 Pisa ,","place":["Italy"]},{"name":"Cardiology Division, Fondazione Toscana Gabriele Monasterio , via Moruzzi 1, 56124 Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9049-5320","authenticated-orcid":false,"given":"Giorgia","family":"Panichella","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London , Royal Free Campus, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9233-9831","authenticated-orcid":false,"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[{"name":"National Amyloidosis Centre, University College London , Royal Free Campus, London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Emdin","sequence":"additional","affiliation":[{"name":"Health Sciences Interdisciplinary Center, Scuola Superiore Sant\u2019Anna , piazza Martiri della Libert\u00e0 33, 56127 Pisa ,","place":["Italy"]},{"name":"Cardiology Division, Fondazione Toscana Gabriele Monasterio , via Moruzzi 1, 56124 Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7066-6006","authenticated-orcid":false,"given":"Giuseppe","family":"Vergaro","sequence":"additional","affiliation":[{"name":"Health Sciences Interdisciplinary Center, Scuola Superiore Sant\u2019Anna , piazza Martiri della Libert\u00e0 33, 56127 Pisa ,","place":["Italy"]},{"name":"Cardiology Division, Fondazione Toscana Gabriele Monasterio , via Moruzzi 1, 56124 Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"2026092207311048100_xvag172-B1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.hfc.2024.09.003","article-title":"Cardiac amyloidosis: how its epidemiology is changing","volume":"20","author":"Panichella","year":"2024","journal-title":"Heart Fail Clin"},{"key":"2026092207311048100_xvag172-B2"},{"key":"2026092207311048100_xvag172-B3"},{"key":"2026092207311048100_xvag172-B4","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1177\/2047487319877708","article-title":"Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings","volume":"27","author":"Vergaro","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"2026092207311048100_xvag172-B5","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026092207311048100_xvag172-B6","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/ejhf.2589","article-title":"Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis","volume":"24","author":"Antonopoulos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026092207311048100_xvag172-B7","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/eurjpc\/zwae093","article-title":"Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study","volume":"31","author":"Aimo","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026092207311048100_xvag172-B8","first-page":"102","article-title":"A systematic review and meta-analysis of the prevalence of transthyretin amyloidosis in heart failure with preserved ejection fraction","volume":"12","author":"Magdi","year":"2022","journal-title":"Am J Cardiovasc Dis"},{"key":"2026092207311048100_xvag172-B9","doi-asserted-by":"publisher","DOI":"10.1097\/gox.0000000000006816","article-title":"Amyloidosis screening by biopsy during carpal tunnel release: a systematic review and meta-analysis","volume":"13","author":"Ferrin","year":"2025","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"2026092207311048100_xvag172-B10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12175698","article-title":"Prevalence of incidental findings suspicious for transthyretin cardiac amyloidosis among patients undergoing bone scintigraphy: a systematic review and a meta-analysis","volume":"12","author":"Treglia","year":"2023","journal-title":"J Clin Med"},{"key":"2026092207311048100_xvag172-B11","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13665","article-title":"Yield of bone scintigraphy screening for transthyretin-related cardiac amyloidosis in different conditions: methodological issues and clinical implications","volume":"51","author":"Tini","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"2026092207311048100_xvag172-B12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.hjc.2021.11.001","article-title":"Prevalence and outcomes of concomitant cardiac amyloidosis and aortic stenosis: a systematic review and meta-analysis","volume":"64","author":"Ho","year":"2022","journal-title":"Hellenic J Cardiol"},{"key":"2026092207311048100_xvag172-B13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.rec.2024.07.005","article-title":"Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study","volume":"78","author":"Garc\u00eda-Pav\u00eda","year":"2025","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026092207311048100_xvag172-B14","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1002\/ejhf.70030","article-title":"High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: the CAPTURE study","volume":"27","author":"Aimo","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026092207311048100_xvag172-B15"},{"key":"2026092207311048100_xvag172-B16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026092207311048100_xvag172-B17","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026092207311048100_xvag172-B18","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s10554-016-0915-z","article-title":"Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy","volume":"32","author":"Bennani Smires","year":"2016","journal-title":"Int J Cardiovasc Imaging"},{"key":"2026092207311048100_xvag172-B19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/13506129.2017.1391086","article-title":"Prevalence of mutant ATTR cardiac amyloidosis in elderly African Americans with heart failure","volume":"24","author":"Arvanitis","year":"2017","journal-title":"Amyloid"},{"key":"2026092207311048100_xvag172-B20","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.cardfail.2016.12.006","article-title":"Baseline characteristics predict the presence of amyloid on endomyocardial biopsy","volume":"23","author":"Ton","year":"2017","journal-title":"J Card Fail"},{"key":"2026092207311048100_xvag172-B21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1080\/13506129.2019.1625322","article-title":"Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders","volume":"26","author":"L\u00f3pez-Sainz","year":"2019","journal-title":"Amyloid"},{"key":"2026092207311048100_xvag172-B22","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jchf.2020.04.007","article-title":"Endomyocardial biopsy characterization of heart failure with preserved ejection fraction and prevalence of cardiac amyloidosis","volume":"8","author":"Hahn","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026092207311048100_xvag172-B23","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026092207311048100_xvag172-B24","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1002\/ehf2.13360","article-title":"Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy","volume":"8","author":"Devesa","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026092207311048100_xvag172-B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0254104","article-title":"Wild-type TTR amyloidosis among patients with unexplained heart failure and systolic LV dysfunction","volume":"16","author":"Goland","year":"2021","journal-title":"PLoS One"},{"key":"2026092207311048100_xvag172-B26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/ehf2.13110","article-title":"Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic","volume":"8","author":"Lindmark","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026092207311048100_xvag172-B27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.regg.2022.10.005","article-title":"Prevalence of transthyretin cardiac amyloidosis in elderly patients diagnosed with heart failure","volume":"58","author":"Jaramillo-Hidalgo","year":"2023","journal-title":"Rev Esp Geriatr Gerontol"},{"key":"2026092207311048100_xvag172-B28","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.122.028973","article-title":"Clinical penetrance of the transthyretin V122I variant in older black patients with heart failure: the SCAN-MP (screening for cardiac amyloidosis with nuclear imaging in minority populations) study","volume":"12","author":"Madhani","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026092207311048100_xvag172-B29","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12062273","article-title":"Estimating the prevalence of cardiac amyloidosis in old patients with heart failure-barriers and opportunities for improvement: the PREVAMIC study","volume":"12","author":"Ruiz-Hueso","year":"2023","journal-title":"J Clin Med"},{"key":"2026092207311048100_xvag172-B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102385","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in patients admitted for acute heart failure","volume":"49","author":"Spaccavento","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"2026092207311048100_xvag172-B31","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/ejhf.3186","article-title":"Prevalence of wild-type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: results of the Amylo-VIP-HF study","volume":"26","author":"Tubben","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026092207311048100_xvag172-B32","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/13506129.2024.2398446","article-title":"International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction","volume":"31","author":"Yun","year":"2024","journal-title":"Amyloid"},{"key":"2026092207311048100_xvag172-B33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12471-025-01954-3","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in an unselected cohort with heart failure with preserved ejection fraction","volume":"33","author":"Achten","year":"2025","journal-title":"Neth Heart J"},{"key":"2026092207311048100_xvag172-B34","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/ehf2.15112","article-title":"Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction","volume":"12","author":"Healy","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026092207311048100_xvag172-B35","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jcin.2012.03.012","article-title":"Pathology of transcatheter valve therapy","volume":"5","author":"Nietlispach","year":"2012","journal-title":"JACC Cardiovasc Interv"},{"key":"2026092207311048100_xvag172-B36","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jcmg.2015.04.012","article-title":"Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis","volume":"9","author":"Longhi","year":"2016","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026092207311048100_xvag172-B37","doi-asserted-by":"publisher","DOI":"10.1161\/circimaging.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026092207311048100_xvag172-B38","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"2026092207311048100_xvag172-B39","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12968-017-0415-x","article-title":"Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis","volume":"19","author":"Cavalcante","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"2026092207311048100_xvag172-B40","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/ejhf.1756","article-title":"Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome","volume":"22","author":"Nitsche","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026092207311048100_xvag172-B41","doi-asserted-by":"publisher","DOI":"10.1161\/circimaging.119.010358","article-title":"Quantification of myocardial extracellular volume with planning computed tomography for transcatheter aortic valve replacement to identify occult cardiac amyloidosis in patients with severe aortic stenosis","volume":"13","author":"Oda","year":"2020","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026092207311048100_xvag172-B42","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1093\/eurheartj\/ehaa170","article-title":"Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation","volume":"41","author":"Scully","year":"2020","journal-title":"Eur Heart J"},{"key":"2026092207311048100_xvag172-B43","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis","volume":"77","author":"Nitsche","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026092207311048100_xvag172-B44","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/ejhf.1974","article-title":"Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis","volume":"23","author":"Rosenblum","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026092207311048100_xvag172-B45","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1002\/ehf2.13667","article-title":"Transthyretin cardiac amyloidosis in patients after TAVR: clinical and echocardiographic findings and long term survival","volume":"8","author":"Shimoni","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026092207311048100_xvag172-B46","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jaccao.2021.08.008","article-title":"Concomitant transthyretin amyloidosis and severe aortic stenosis in elderly Indian population: a pilot study","volume":"3","author":"Singal","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2026092207311048100_xvag172-B47","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.acvd.2024.04.007","article-title":"Cardiac amyloidosis prevalence and 1-year outcome in patients with aortic stenosis undergoing transaortic valve implantation: findings from the CAMPOS-TAVI study","volume":"117","author":"Costa","year":"2024","journal-title":"Arch Cardiovasc Dis"},{"key":"2026092207311048100_xvag172-B48","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13030671","article-title":"Screening for occult transthyretin amyloidosis in patients with severe aortic stenosis and amyloid red flags","volume":"13","author":"Jakstaite","year":"2024","journal-title":"J Clin Med"},{"key":"2026092207311048100_xvag172-B49","doi-asserted-by":"publisher","first-page":"384","DOI":"10.62347\/hjht9161","article-title":"Prevalence of transthyretin cardiac amyloidosis in patients with aortic stenosis","volume":"14","author":"SadrAldin","year":"2024","journal-title":"Am J Cardiovasc Dis"},{"key":"2026092207311048100_xvag172-B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahjo.2025.100575","article-title":"CT derived ECV in severe aortic stenosis: prognosticator and screening test for co-existent transthyretin cardiac amyloidosis","volume":"56","author":"McShane","year":"2025","journal-title":"Am Heart J Plus"},{"key":"2026092207311048100_xvag172-B51","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","article-title":"Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release","volume":"72","author":"Sperry","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026092207311048100_xvag172-B52","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s12265-019-09895-0","article-title":"Prevalence of cardiac amyloidosis in patients with carpal tunnel syndrome","volume":"12","author":"Zegri-Reiriz","year":"2019","journal-title":"J Cardiovasc Transl Res"},{"key":"2026092207311048100_xvag172-B53","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.amjcard.2021.08.049","article-title":"Cardiac amyloidosis screening at trigger finger release surgery","volume":"160","author":"Sperry","year":"2021","journal-title":"Am J Cardiol"},{"key":"2026092207311048100_xvag172-B54","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1253\/circrep.CR-21-0046","article-title":"Tenosynovial and cardiac transthyretin amyloidosis in Japanese patients undergoing carpal tunnel release","volume":"3","author":"Sugiura","year":"2021","journal-title":"Circ Rep"},{"key":"2026092207311048100_xvag172-B55","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijcard.2020.12.044","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in male patients who underwent bilateral carpal tunnel surgery: the ACTUAL study","volume":"329","author":"Vianello","year":"2021","journal-title":"Int J Cardiol"},{"key":"2026092207311048100_xvag172-B56","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jhsg.2022.08.008","article-title":"Prevalence of amyloid deposition in patients undergoing surgical repair of traumatic distal biceps tendon ruptures","volume":"4","author":"Baylor","year":"2022","journal-title":"J Hand Surg Glob Online"},{"key":"2026092207311048100_xvag172-B57","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jacc.2022.06.026","article-title":"Screening for cardiac amyloidosis 5 to 15 years after surgery for bilateral carpal tunnel syndrome","volume":"80","author":"Westin","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026092207311048100_xvag172-B58","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.jaccao.2023.05.012","article-title":"Prospective screening for transthyretin cardiac amyloidosis in spinal stenosis surgery patients: results of the CASS study","volume":"5","author":"Debonnaire","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2026092207311048100_xvag172-B59","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1253\/circj.CJ-23-0223","article-title":"Prevalence of cardiac amyloidosis in patients undergoing carpal tunnel release with amyloid deposition","volume":"87","author":"Takashio","year":"2023","journal-title":"Circ J"},{"key":"2026092207311048100_xvag172-B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132114","article-title":"Screening for cardiac amyloidosis in patients with tenosynovial red flags: a collaboration between family medicine and cardiology","volume":"407","author":"Andrei","year":"2024","journal-title":"Int J Cardiol"},{"key":"2026092207311048100_xvag172-B61","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jhsa.2022.09.005","article-title":"Results of implementation of amyloidosis screening for patients undergoing carpal tunnel release","volume":"49","author":"Gannon","year":"2024","journal-title":"J Hand Surg Am"},{"key":"2026092207311048100_xvag172-B62","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jseint.2023.11.009","article-title":"Prevalence of amyloid deposition and cardiac amyloidosis in shoulder disease compared to carpal tunnel syndrome","volume":"8","author":"Yamada","year":"2024","journal-title":"JSES Int"},{"key":"2026092207311048100_xvag172-B63","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1080\/13506129.2025.2481310","article-title":"Cardiac amyloidosis after lumbar spinal stenosis surgery\u2014a comprehensive prospective cohort study","volume":"32","author":"Eldhagen","year":"2025","journal-title":"Amyloid"},{"key":"2026092207311048100_xvag172-B64","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14113710","article-title":"Screening for cardiac amyloidosis when conducting carpal tunnel surgery","volume":"14","author":"Pimenta","year":"2025","journal-title":"J Clin Med"},{"key":"2026092207311048100_xvag172-B65","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/bf00838945","article-title":"Clinical significance of technetium-99 m methylene diphosphonate myocardial uptake: association with carcinoma of the prostate","volume":"22","author":"al-Nahhas","year":"1995","journal-title":"Eur J Nucl Med"},{"key":"2026092207311048100_xvag172-B66","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jcmg.2014.03.004","article-title":"Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy","volume":"7","author":"Longhi","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026092207311048100_xvag172-B67","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ijcard.2018.06.006","article-title":"Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population","volume":"270","author":"Mohamed-Salem","year":"2018","journal-title":"Int J Cardiol"},{"key":"2026092207311048100_xvag172-B68","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1536\/ihj.18-345","article-title":"Prevalence of positive (99 m)Tc-DPD scintigraphy as an indicator of the prevalence of wild-type transthyretin amyloidosis in the elderly","volume":"60","author":"Kim","year":"2019","journal-title":"Int Heart J"},{"key":"2026092207311048100_xvag172-B69","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s12350-021-02575-0","article-title":"The prevalence of TTR cardiac amyloidosis among patients undergoing bone scintigraphy","volume":"28","author":"Bianco","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"2026092207311048100_xvag172-B70","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s12350-020-02152-x","article-title":"Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation","volume":"28","author":"Cuscaden","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"2026092207311048100_xvag172-B71","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13550-022-00897-9","article-title":"Convolutional neural networks for detection of transthyretin amyloidosis in 2D scintigraphy images","volume":"12","author":"Halme","year":"2022","journal-title":"EJNMMI Res"},{"key":"2026092207311048100_xvag172-B72","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.2967\/jnumed.122.264041","article-title":"Prevalence and outcomes of cardiac amyloidosis in all-comer referrals for bone scintigraphy","volume":"63","author":"Nitsche","year":"2022","journal-title":"J Nucl Med"},{"key":"2026092207311048100_xvag172-B73","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1007\/s12350-022-02961-2","article-title":"Incidental cardiac uptake of (99 m)Tc-diphosphonates is predictive of poor outcome: data from 9616 bone scintigraphies","volume":"29","author":"Salvalaggio","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"2026092207311048100_xvag172-B74","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s12350-020-02396-7","article-title":"Prognostic significance of incidental suspected transthyretin amyloidosis on routine bone scintigraphy","volume":"29","author":"Suomalainen","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"2026092207311048100_xvag172-B75","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s10554-023-02840-y","article-title":"Trends in diagnosis of cardiac transthyretin amyloidosis: 3-year analysis of scintigraphic studies: prevalence of myocardial uptake and its predictor factors","volume":"39","author":"Navarro-Saez","year":"2023","journal-title":"Int J Cardiovasc Imaging"},{"key":"2026092207311048100_xvag172-B76","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s44348-024-00030-5","article-title":"Prevalence and characteristics of patients with incidental cardiac uptake on bone scintigraphy","volume":"32","author":"Son","year":"2024","journal-title":"J Cardiovasc Imaging"},{"key":"2026092207311048100_xvag172-B77","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/13506129.2017.1333956","article-title":"Diagnostic score for the detection of cardiac amyloidosis in patients with left ventricular hypertrophy and impact on prognosis","volume":"24","author":"Cariou","year":"2017","journal-title":"Amyloid"},{"key":"2026092207311048100_xvag172-B78","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.ijcard.2019.07.051","article-title":"Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy","volume":"300","author":"Maurizi","year":"2020","journal-title":"Int J Cardiol"},{"key":"2026092207311048100_xvag172-B79","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12947-021-00258-x","article-title":"Cardiac amyloidosis screening using a relative apical sparing pattern in patients with left ventricular hypertrophy","volume":"19","author":"Nakao","year":"2021","journal-title":"Cardiovasc Ultrasound"},{"key":"2026092207311048100_xvag172-B80","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/ejhf.2504","article-title":"Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey","volume":"24","author":"Merlo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026092207311048100_xvag172-B81","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.cjca.2024.10.010","article-title":"Prevalence of cardiac amyloidosis among elderly patients with recent-onset atrial fibrillation: the PREVAL-ATTR study","volume":"41","author":"Remior-P\u00e9rez","year":"2025","journal-title":"Can J Cardiol"},{"key":"2026092207311048100_xvag172-B82","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1253\/circj.CJ-23-0948","article-title":"Efficacy of computed tomography-based evaluation of myocardial extracellular volume combined with red flags for early screening of concealed cardiac amyloidosis in patients with atrial fibrillation","volume":"88","author":"Yamasaki","year":"2024","journal-title":"Circ J"},{"key":"2026092207311048100_xvag172-B83","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1093\/eurheartj\/ehaf332","article-title":"Atrial amyloidosis identified by biopsy in atrial fibrillation: prevalence and clinical presentation","volume":"46","author":"Shinzato","year":"2025","journal-title":"Eur Heart J"},{"key":"2026092207311048100_xvag172-B84","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.749523","article-title":"Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post-mortem examination","volume":"8","author":"Porcari","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026092207311048100_xvag172-B85","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1253\/circj.CJ-24-0479","article-title":"Prospective multicenter screening with high-sensitivity cardiac troponin T for wild-type transthyretin cardiac amyloidosis in outpatient and community-based settings","volume":"89","author":"Arima","year":"2024","journal-title":"Circ J"},{"key":"2026092207311048100_xvag172-B86","doi-asserted-by":"publisher","DOI":"10.1111\/ene.16065","article-title":"Genetic screening for hereditary transthyretin amyloidosis with polyneuropathy in western Sicily: two years of experience in a neurological clinic","volume":"31","author":"Di Stefano","year":"2024","journal-title":"Eur J Neurol"},{"key":"2026092207311048100_xvag172-B87","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00415-025-13218-6","article-title":"Prevalence of hereditary transthyretin amyloidosis in CIDP patients with red flags: a multicenter genetic screening and misdiagnosis analysis","volume":"272","author":"Doneddu","year":"2025","journal-title":"J Neurol"},{"key":"2026092207311048100_xvag172-B88","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1002\/mus.26348","article-title":"Screening for Fabry disease and Hereditary ATTR amyloidosis in idiopathic small-fiber and mixed neuropathy","volume":"59","author":"Samuelsson","year":"2019","journal-title":"Muscle Nerve"},{"key":"2026092207311048100_xvag172-B89","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/ajh.27545","article-title":"Feasibility of a biomarker-based screening for pre-symptomatic AL amyloidosis in patients with intermediate\/high-risk MGUS","volume":"100","author":"Mangiacavalli","year":"2025","journal-title":"Am J Hematol"},{"key":"2026092207311048100_xvag172-B90","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14124146","article-title":"Screening for systemic light-chain amyloidosis in patients over 60 with \u03bb monoclonal gammopathies","volume":"14","author":"Zhou","year":"2025","journal-title":"J Clin Med"},{"key":"2026092207311048100_xvag172-B91","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.rec.2023.12.006","article-title":"Results of a population screening program for hereditary transthyretin amyloidosis","volume":"77","author":"de Frutos","year":"2024","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026092207311048100_xvag172-B92","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci15040365","article-title":"Genetic screening for hereditary transthyretin amyloidosis in the population of cammarata and san giovanni gemini through red flags and registry archives","volume":"15","author":"Di Stefano","year":"2025","journal-title":"Brain Sci"},{"key":"2026092207311048100_xvag172-B93","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N Engl J Med"},{"key":"2026092207311048100_xvag172-B94","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1186\/s13104-016-2263-4","article-title":"Endomyocardial biopsy in patients with cardiomyopathy of unknown origin: does specialized center experience apply to a tertiary care hospital?","volume":"9","author":"Tebbe","year":"2016","journal-title":"BMC Res Notes"},{"key":"2026092207311048100_xvag172-B95","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2024-002606","article-title":"Prevalence of transthyretin cardiac amyloidosis in patients with high-degree AV block","volume":"11","author":"Cannie","year":"2024","journal-title":"Open Heart"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag172\/68570182\/xvag172.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/5\/xvag172\/68570182\/xvag172.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/5\/xvag172\/68570182\/xvag172.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:31:19Z","timestamp":1790076679000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag172\/8713046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":95,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,6,22]]},"published-print":{"date-parts":[[2026,8,27]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag172","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,6,22]]},"article-number":"xvag172"}}